Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06278207 · ClinicalTrials.gov registry record

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

A clinical trial of Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Bayer.

Recruiting
Registry status
50,000
Enrollment target
4
Study locations

NCT06278207: Recruiting study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Bayer.

NCT06278207 is a study of Type 2 Diabetes Mellitus and Chronic Kidney Disease that is actively recruiting participants, run by Bayer. The registered enrollment target is 50,000 participants, above the 2,575-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (1842% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06278207, a study of Type 2 Diabetes Mellitus and Chronic Kidney Disease, is actively recruiting participants, sponsored by Bayer.

RECRUITING
Registry status
50,000 participants
Enrollment target
4
Study locations

Study Summary

This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems. The researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone. The data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests

Primary Outcome

Sociodemographic characteristics such as age, sex, race and socio-economic status.

Interventions

  • DRUG Finerenone (BAY 94-8862)

Study Locations (4)

Other

  • Bayer - Berlin
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations

New Jersey

  • Many Locations - Multiple Locations

Trial Details

FieldValue
Enrollment Target 50,000 participants
Start Date 2024-05-15
Est. Completion 2026-03-31
Bayer

591 total trials

What NCT06278207 shows while recruiting

NCT06278207 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,575-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (1842% higher).

The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Finerenone (BAY 94-8862) is the first listed.

NCT06278207 reports a single indexed study location in Other, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06278207 about?

NCT06278207 is a clinical study titled "An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions". This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their d...

What is the current status of trial NCT06278207?

This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2024-05-15. Estimated completion is 2026-03-31.

What conditions does trial NCT06278207 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease.

What interventions are being tested in trial NCT06278207?

The interventions under investigation include: Finerenone (BAY 94-8862) (DRUG).

Who is sponsoring clinical trial NCT06278207?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06278207 being conducted?

This trial has 4 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06278207's enrollment target sits among peer trials

50,000 3rd of 130 higher than 128 of 130 other Type 2 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00500123 · 50,000 participants

    The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

  • NCT01885299 · 50,000 participants

    RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

  • NCT03452774 · 50,000 participants

    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • NCT04629586 · 50,000 participants

    The T1D Exchange Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06278207, the US trial registry maintained by the National Library of Medicine. NCT06278207 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.